InDex Pharmaceuticals Holding AB
STO:FLERIE
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
8.8
75.4
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one FLERIE stock under the Base Case scenario is 5.65 SEK. Compared to the current market price of 45 SEK, InDex Pharmaceuticals Holding AB is Overvalued by 87%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
InDex Pharmaceuticals Holding AB
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for FLERIE cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
InDex Pharmaceuticals Holding AB
Balance Sheet Decomposition
InDex Pharmaceuticals Holding AB
Current Assets | 987.4m |
Cash & Short-Term Investments | 882.2m |
Receivables | 90.6m |
Other Current Assets | 14.6m |
Non-Current Assets | 3.4B |
Long-Term Investments | 100k |
PP&E | 1.3m |
Other Non-Current Assets | 3.4B |
Current Liabilities | 31.6m |
Accounts Payable | 1.1m |
Accrued Liabilities | 19.3m |
Other Current Liabilities | 11.2m |
Non-Current Liabilities | 3.1m |
Long-Term Debt | 700k |
Other Non-Current Liabilities | 2.4m |
Earnings Waterfall
InDex Pharmaceuticals Holding AB
Revenue
|
100k
SEK
|
Cost of Revenue
|
-127m
SEK
|
Gross Profit
|
-126.9m
SEK
|
Operating Expenses
|
-111.9m
SEK
|
Operating Income
|
-238.9m
SEK
|
Other Expenses
|
48.5m
SEK
|
Net Income
|
-190.4m
SEK
|
Free Cash Flow Analysis
InDex Pharmaceuticals Holding AB
SEK | |
Free Cash Flow | SEK |
FLERIE Profitability Score
Profitability Due Diligence
InDex Pharmaceuticals Holding AB's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
InDex Pharmaceuticals Holding AB's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
FLERIE Solvency Score
Solvency Due Diligence
InDex Pharmaceuticals Holding AB's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
InDex Pharmaceuticals Holding AB's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FLERIE Price Targets Summary
InDex Pharmaceuticals Holding AB
According to Wall Street analysts, the average 1-year price target for FLERIE is 47.26 SEK with a low forecast of 27.27 SEK and a high forecast of 71.4 SEK.
Dividends
Current shareholder yield for FLERIE is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
InDex Pharmaceuticals Holding AB engages in the development of drugs for the treatment of diseases such as inflammation and cancer. The company is headquartered in Solna, Stockholm and currently employs 6 full-time employees. The company went IPO on 2016-10-11. The firm is focused in pharmaceuticals development. The firm's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The firm also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohn’s disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.
Contact
IPO
Employees
Officers
The intrinsic value of one FLERIE stock under the Base Case scenario is 5.65 SEK.
Compared to the current market price of 45 SEK, InDex Pharmaceuticals Holding AB is Overvalued by 87%.